Invesco Biotechnology & Genome ETF
PBE
77 hedge funds and large institutions have $53.4M invested in Invesco Biotechnology & Genome ETF in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
1% more funds holding
Funds holding: 76 → 77 (+1)
1.19% less ownership
Funds ownership: 23.23% → 22.03% (-1.2%)
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
47% less capital inflows, than outflows
Capital inflows: $3.7M | Capital outflows: $6.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Anfield Capital Management
Irvine,
California
|
+$970K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$599K |
| 3 |
Morgan Stanley
New York
|
+$318K |
| 4 |
Raymond James & Associates
St Petersburg,
Florida
|
+$281K |
| 5 |
Neuberger Berman Group
New York
|
+$218K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.77M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.54M |
| 3 |
Brinker Capital Investments
Berwyn,
Pennsylvania
|
-$1.26M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$661K |
| 5 |
Jane Street
New York
|
-$568K |
PBE Hedge Fund Activity: Q2 2020 in Review
77 of the 4,890 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2020, worth a combined $53.4M — up 15% from $46.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PBE positions and 7 closed out — a net gain of 2 holders — while 18 added to existing stakes and 21 trimmed.
The largest buyer was Anfield Capital Management, adding an estimated $970K. The largest seller was Citadel Advisors, exiting entirely with an estimated $1.77M sold.
- 77 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2020, up from 76 in Q1 2020.
- Funds reported $53.4M of Invesco Biotechnology & Genome ETF stock for Q2 2020, up 15% quarter-over-quarter.
- 9 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2020 and 7 closed out, a net change of +2 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2020 was Anfield Capital Management, an estimated $970K added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2020 was Citadel Advisors, an estimated $1.77M sold.
Based on aggregated 13F filings for Q2 2020.